Welcome to our dedicated page for Fate Therapeutic SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fate Therapeutics files SEC reports that document its clinical-stage biopharmaceutical business and its iPSC-derived cellular immunotherapy pipeline for cancer and autoimmune diseases. Current reports furnish operating results and business updates, including disclosures on FT819, FT836 and other off-the-shelf CAR T-cell programs, FDA-related development matters, clinical presentations, and costs associated with restructuring actions.
Proxy and current-report filings cover board and compensation governance, equity-plan matters, Regulation FD disclosures, and capital-structure details for FATE common stock listed on the Nasdaq Global Market. The filings also record material events affecting operations and public-company reporting obligations.
Fate Therapeutics (FATE) filed a Form 3, the initial statement of beneficial ownership for its Chief Financial Officer under Section 16. The filing states that no securities are beneficially owned by the reporting person as of the event date 10/20/2025. The form was filed by one reporting person, with a Power of Attorney on file (Exhibit 24) and signed by Cindy Tahl, as Attorney-in-Fact on 10/21/2025.
Fate Therapeutics filed a Form S-8 to register 1,750,000 additional shares of common stock for issuance under its Amended and Restated Inducement Equity Plan.
The Board approved the increase on October 13, 2025, adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The filing uses General Instruction E to register additional securities and incorporates the prior S-8 (File No. 333-253459).
Pursuant to Rule 416(a), the registration also covers an indeterminate number of additional shares for anti‑dilution and other adjustments.
Fate Therapeutics (FATE) reported board and leadership changes. On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian notified the company of their resignations from the Board, effective October 13, 2025. The company stated both resignations were voluntary and not due to any disagreement on operations, practices, or policies. Following these changes, the Board size was reduced from 10 to 8 directors, effective October 13, 2025.
On October 13, 2025, the Board approved the appointment of Kamal Adawi, M.S., M.B.A., as Chief Financial Officer, effective October 20, 2025. He was also designated principal financial officer and principal accounting officer, replacing Bahram Valamehr in those roles; Dr. Valamehr continues as Director and as President and Chief Executive Officer. The company furnished a press release on October 14, 2025 announcing Mr. Adawi’s appointment.
Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they collectively hold 2,274,020.09 shares of Fate Therapeutics common stock, representing 2.0% of the class. The cover pages report shared voting power of 2,273,623.09 shares and shared dispositive power of 2,274,020.09 shares.
The filing includes a joint filing agreement (Exhibit 99.1) and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. (Exhibit 99.2). The filing further certifies the securities are held in the ordinary course of business and not for the purpose of changing control. The statement is signed by Veronica Mupazviriwo as attorney-in-fact on behalf of both reporting persons.
Fate Therapeutics (FATE) reported that on August 7, 2025 its Board approved a corporate restructuring to streamline operations, reduce operating expenses and extend the company’s cash runway. The company committed to a reduction in total workforce of approximately 12% and informed affected employees on August 12, 2025.
The company expects the reduction-in-force to complete in the third quarter of 2025 and estimates it will incur charges of approximately $0.9 million to $1.2 million for severance and other employee termination-related costs. A press release with the quarter-end results is attached as Exhibit 99.1, and the information is furnished, not filed, under the Exchange Act.